Skip to content

Evaluation of the hemostatic effect of desmopressin nasal spray in rhinoplasty

Hemostatic effect of desmopressin nasal spray in rhinoplasty

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210424051060N1
Enrollment
88
Registered
2021-05-18
Start date
2021-05-04
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinoplasty.

Interventions

Intervention 1: Intervention group: One hour before the start of nasal spray surgery, desmopressin will be given, two puffs on each side of the nose, giving the patient a total of 40 micrograms of des

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Hemoglobin above 10 Patients without coagulation disorders

Exclusion criteria

Exclusion criteria: Coagulant disorder A condition associated with clot such as CVA, thrombosis Drug sensitivity to desmopressin Hypertension Taking drugs that affect coagulation

Design outcomes

Primary

MeasureTime frame
Bleeding. Timepoint: In the 30th and 60th minutes after the start of surgery. Method of measurement: According to Beozaart criteria.

Secondary

MeasureTime frame
Surgeon satisfaction. Timepoint: At the end of surgery. Method of measurement: According to the Likert scale.;Length of surgery. Timepoint: End of surgery. Method of measurement: Surgery time based on minutes.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohreh Nazarpour Sarvak

Shiraz University of Medical Sciences

Zohrenazarpour@gmail.com+98 915 709 0986

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026